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Synthesis of thyroid hormones, thyroxine (T4) and tri-iodothyronine (T3), in the human
fetus starts from 17 to 19th weeks of gestation. Despite the majority of normal pregnant
women reaching adequate levels of circulating thyroid hormones, in some cases, women
with normal pregnancies have low level of free T4 during first trimester of pregnancy,
suggesting that T4 action may be compromised in those women and their fetuses. In
addition, pathological low levels of thyroid hormones are detected in isolated maternal
hypothyroxemia (IMH) and clinical hypothyroidism. Nevertheless, human placenta regu-
lates T3/T4 concentration in the fetal circulation by modulating the expression and activity
of both thyroid hormone transporters (THT) and deiodinases.Then, placenta can control the
availability ofT3/T4 in the feto-placental circulation, and therefore may generate an adaptive
response in cases where the mother courses with low levels ofT4. In addition,T3/T4 might
control vascular response in the placenta, in particularly endothelial cells may induce the
synthesis and release of vasodilators such as nitric oxide (NO) or vasoconstrictors such as
endothelin-1 mediated by these hormones. On the other hand, low levels of T4 have been
associated with increase in gestational diabetes (GD) markers. Since GD is associated
with impaired placental vascular function characterized by increased NO synthesis in
placental arteries and veins, as well as elevated placental angiogenesis, it is unknown
whether reduced T4 level at the maternal circulation could result in an altered placental
endothelial function during GD. In this review, we analyze available information regarding
thyroid hormones and endothelial dysfunction in GD; and propose that low maternal levels
of T4 observed in GD may be compensated by increased placental availability of T3/T4
via elevation in the activity of THT and/or reduction in deiodinases in the feto-placental
circulation.
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INTRODUCTION
Thyroid gland produces tetra-iodothyronine (T4 or thyroxine)
and tri-iodothyronine (T3). In the human fetus, the synthesis of
these hormones starts from 17 to 19th weeks of gestation (wg),
therefore it is well accepted that before this period, the circulat-
ing T3/T4 in the fetus depends on the maternal levels of these
hormones (Pérez-López, 2007). Thus, an altered function of the
thyroid gland at the maternal side could prejudice physiological
levels of T3/T4 at the fetal circulation, and impair fetal growth and
development. Worldwide studies indicate that ∼10% of women
may have hypothyroidism in their childbearing age (Mosso et al.,
2012; Khalid et al., 2013; Ohashi et al., 2013). It has been also
described that ∼35 or ∼3% of women with an apparent nor-
mal pregnancy have clinical hypothyroidism or exhibit maternal
hypothyroxemia (low level of free T4), respectively (Mosso et al.,
2012), bothmaternal conditions associatedwith several alterations
in the fetus development (Parkes et al., 2012). Nevertheless, iso-
lated maternal hypothyroxemia (IMH), a pathological condition
manifested during pregnancy (Sahay andNagesh,2012), have been
associated with occurrence of gestational diabetes (GD; Olivieri
et al., 2000), pre-eclampsia (Sardana et al., 2009), or intrauterine
growth restriction, IUGR; Chan et al., 2006). Moreover, pregnant
women with IMH have higher risk (fourfold) to develop insulin
resistance and GD (Karakosta et al., 2012; Tudela et al., 2012). In
fact, reduced T4 level in the maternal circulation is associated with
an increase in the incidence of GD pregnancies (Olivieri et al.,
2000; Tudela et al., 2012) and with altered development of the
central nervous system in children from pregnancies affected by
these diseases (Smallridge and Ladenson, 2001; Casey et al., 2005).
In addition, an incidence as high as ∼70% of women coursing
with pregnancies affected with GD exhibit IMH (Olivieri et al.,
2000).
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Gestational diabetes (GD) is associated with higher synthe-
sis and release of vasodilators such as nitric oxide (NO) in the
human fetal endothelium from GD (described as altered endothe-
lial function) (De Vriese et al., 2000; Guzmán-Gutiérrez et al.,
2011; Westermeier et al., 2011; Salomón et al., 2012). In addi-
tion, thyroid hormones are also involved in NO synthesis and
release (Napoli et al., 2001; Fazio et al., 2004), but the potential
contribution of reduced circulating T4 on deregulation of fetal
endothelial function seen in GD pregnancies is unclear. We here
analyze the available information regarding the potential rela-
tionship between maternal and fetal thyroid hormones with the
occurrence of endothelial dysfunction in GD. We propose that
the low maternal levels of T4 seen in GD may be compensated
by higher placental availability of thyroid hormones via eleva-
tion in the activity of placental thyroid hormone transport and
metabolism.
OVERVIEW OF SYNTHESIS AND RELEASE OF THYROID
HORMONES
The thyroid hormones 3,5,3′,5′-tetraiodothyronine (T4 or thy-
roxine) and 3,5,3′-triiodothyronine (T3) are synthesized in the
thyroid gland and is regulated by hypothalamus/pituitary/thyroid
axis by a negative feedback. In this regulatory axis, hypotha-
lamus releases thyrotropin releasing hormone (TRH), which
interacts with TRH receptors in thyrotropin cells in the pitu-
itary gland to release thyroid stimulating hormone (TSH). In
turn, TSH is the main regulator of the release of thyroid hor-
mones leading to TSH receptor (TSHr) activation and increased
iodo (iodide) uptake in the thyroid gland (Szkudlinski et al.,
2002).
Iodide intracellular uptake is mediated by cotransport with
sodium (Na+/I−) in the basal membrane of follicular cells in
the thyroid gland. In these cells, iodides are oxidized by thy-
roid peroxidase (TPO) in the presence of hydrogen peroxide.
Iodine (oxidized iodine) binds to thyroxine residues belong to
the tiroglobulins (Tg), then tyroxine residues can be mono (MIT),
di (DIT), tri (T3), or tetra-iodinated (T4) (Sugenoya et al., 1984;
Rousset, 1991). The release of thyroid hormones through the
basolateral membrane in thyroid gland follicular cells requires
endocytosis of iodinated Tg at the apical side of these cells.
The Tg is then incorporated into phagolysosomes and digested
by proteolytic proteins, with MIT and DIT being re-uptaked
into Tg; however, T3 and T4 are released toward circulation
(Rousset, 1991). T4 is the main thyroid hormone released by thy-
roid gland follicular cells (∼40-fold compared with T3) and is
almost all (99.97%) bound to thyroxine binding globulin (TBG),
albumin and pre-albumin in the circulation. In addition, free
T3 accounts for ∼0.3% and the rest is bound to TBG and
albumin.
Free T3 is the hormone with biological activity and is the active
form of thyroid hormones. It is derived from 5′-deiodination
of free T4 via iodothyronine deiodinases located in the target
tissues (Sugenoya et al., 1984; Rousset, 1991; Schussler, 2000;
Bianco and Kim, 2006). Deiodinases are grouped in three sub-
types: I, II, and III (or D1, D2, and D3, respectively), all of
which are involved in the regulation of T3 activity (Bianco and
Kim, 2006; Darras and Van Herck, 2012). For instance, D2 is
specific to generate T3 from T4; however, D3 generates DIT
from T3, and reverse T3 (rT3, inactive form of T3) from T4
(Kilby et al., 2005). D1 has been reported as an enzyme that is
much less active compared with the other forms (Bianco and
Kim, 2006; Dentice and Salvatore, 2011; Darras and Van Herck,
2012).
VASCULAR EFFECTS OF THYROID HORMONES
Thyroid hormones reduce peripheral vascular resistance by pro-
moting relaxation in human and murine vascular smooth-muscle
cells (Klemperer et al., 1995; Ojamaa et al., 1996; Park et al., 1997),
and improve vascular reactivity by endothelium-dependent and
-independent mechanisms (Napoli et al., 2001; Fazio et al., 2004).
In rat, T4 released from the mesenteric arteries increases vasore-
laxation when administrated at supraphysiological concentrations
(Zwaveling et al., 1997). Moreover, T3 and T4 improve fibroblast
growth factor-2 (FGF-2) expression, a recognized proangiogenic
factor, in cultures of ECV304 cells (Davis et al., 2004). Interestingly,
human umbilical vein endothelial cells (HUVEC) exposed to high
T3 levels exhibit high expression of endothelin-1 (vasoconstrictor)
and fibronectin (profibrotic molecule), suggesting that patholog-
ical conditions such as hyperthyroidism could be associated with
vasoconstriction (Baumgartner-Parzer et al., 1997; Diekman et al.,
2001).
In addition, there is evidence that vasoconstriction associ-
ated with high levels of thyroid hormones may result from a
non-genomic action, which seems mediated by αvβ3 integrin as
reported in HUVEC (Luidens et al., 2010). In this regard, αvβ3
integrin is a membrane protein that should active the phos-
phatidylinositol 3 kinase and protein kinase B/Akt (PI3K/Akt)
pathway in this cell type (Hiroi et al., 2006; Luidens et al.,
2010). Nevertheless, in another study HUVEC and bovine aortic
endothelial cells (BAEC) seems to respond to T3 by increas-
ing the phosphorylation of serine1177 (Ser1177; Ser1177-eNOS) at
the endothelial nitric oxide synthase isotype (eNOS) in a time-
and concentration-dependent manner (Hiroi et al., 2006). Sim-
ilar results were seen in vascular smooth-muscle cells from rat
thoracic aortae where T3 increases Ser1177-eNOS via PI3K/Akt
pathway inducing eNOS, inducible (iNOS) and neuronal (nNOS)
NOS expression. Thus, it is likely that T3 increases NOS expression
via a genomic and a non-genomic (i.e., via αvβ3 integrin) action
(Carrillo-Sepúlveda et al., 2010). Therefore, the thyroid hormone
concentration is a determinant factor involved in the modulation
of vascular function (Figure 1). However, there is not information
addressing thyroid hormone effects on the human feto-placental
vasculature.
HUMAN THYROID HORMONES IN PREGNANCY
Human fetal thyroid hormones are secreted from the 17 to
19 wg, indicating that the fetus requires thyroid hormones
delivery from the mother during the first and beginning of
the second trimester of pregnancy (Pérez-López, 2007). Preg-
nant women have TSH and free T4 levels that are normal
and comparable to those in non-pregnant women; however,
in the first trimester of pregnancy, there is an increase in the
maternal free T4 level most likely in response to chorionic
gonadotropin hormone (hCG; Fantz et al., 1999; Pérez-López,
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FIGURE 1 |Thyroids hormones effects on endothelial cells. T4 (Tyrosine)
is metabolized by deiodinase 2 (D2) to T3 (triiodothyronine) of manner
extra and intracellular. T3 and T4 (Tyrosine) could activates αvβ3 integrin
receptor which initiate a signaling that involve PI3K, Akt and eNOS,
generating nitric oxide (NO) as vasodilator. But, also T3 and T4 are uptake
by thyroid hormones transporters (THT). T3 bind to DNA and activate
transcriptional activity for endothelin-1 and fibronectin which are
associated with vasoconstriction.
2007). It has been shown that increased hCG level leads to reduced
hypothalamus/pituitary/thyroid axis activity, but improved thy-
roid hormones delivery to the fetus in the first trimester of
pregnancy (Fantz et al., 1999; Pérez-López, 2007; Chan et al.,
2009). In this period, the concentration of free T4 in the fetal
circulation corresponds to a third of the level found in the mater-
nal circulation (Chan et al., 2009). This phenomenon results from
a reduced concentration of the TBG binding protein in the fetal
circulation, which leads to a free T4 concentration enough to exert
its biological effects in embryonic tissues (Kilby et al., 2005; Chan
et al., 2009). In the second trimester of pregnancy, free T4 levels
in the fetal circulation corresponds to about half of the concen-
tration detected in the maternal circulation (Kilby et al., 2005;
Chan et al., 2009). Therefore, it seems clear that thyroid hormone
levels are regulated by the placenta tissue (Burrow et al., 1994).
Thus, a role of this organ is crucial in the delivery of T4 to the
fetus.
THYROID HORMONES METABOLISM IN THE HUMAN
PLACENTA
In addition to the paracrine effect of hCG on the hypothala-
mus/pituitary/thyroid axis, the human placenta regulates directly
the thyroid hormone concentration in the fetal circulation
by modulation of thyroid hormone transporters (THT), and
by thyroid hormones metabolism mediated by deiodinases
(Burrow et al., 1994). THT are located at the apical and basolat-
eral membranes of the cytotrophoblasts, syncytiotrophoblast and
microvascular endothelial cells (James et al., 2007). There are sev-
eral THT, including monocarboxylate transporters (MCT), where
MCT8 and MCT10 are the main forms. Moreover, a role has
been reported for L-amino acid transporters (LAT) and organic
anion transporter polypeptides system (OATPs), which oper-
ates with less selectivity for T4 (James et al., 2007). Also in the
human placenta MCT8 (Park and Chatterjee, 2005), MCT10,
LAT1, LAT2 (Friesema et al., 2003), OATP1A2 and OATP4A1
(Hagenbuch and Meier, 2003; Hagenbuch, 2007) have been iden-
tified, but no studies addressing the role of these membrane
transporters in any pathology of pregnancy have been docu-
mented. Moreover, D2 (located at the endoplasmatic reticulum)
and D3 (located at the plasma membrane with a cytoplasmic
active site; Koopdonk-Kool et al., 1996; Stulp et al., 1998; Chan
et al., 2003) have been identified. D2 and D3 are referred as
major factors controlling transplacental transport of T4 to the
fetus (Mortimer et al., 1996). Interestingly, D2 and D3 expres-
sion is up regulated by T3 (Chan et al., 2003). In addition,
since changes in the level of T3/T4 cause altered THT expression
(Mortimer et al., 1996), modulation of D2/D3 and THT expres-
sion by T3/T4 could be a phenomenon serving as a defense
mechanism for the fetus in pregnancies where the mother courses
with hypothyroxemia.
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ISOLATED MATERNAL HYPOTHYROXEMIA AND CLINICAL
HYPOTHYROIDISM
The pathologies associated with low levels of free T4 correspond
to IMH and clinical hypothyroidism. IMH (1–2% of normal
pregnancies) is characterized by low free T4 (<10th percentile in
normal range), but normal TSH level. Instead, clinical hypothy-
roidism characterizes by high levels of TSH, but low levels of
free T4 (Casey et al., 2005). In another pathological condition
referred as “low T3 syndrome,” an increase in the expression of
the membrane transporters MCT8 is reported, which could be a
compensatory response to low levels of thyroid hormones (Mebis
et al., 2009). The latter seems paralleled by an increase in the
D1 and D2 levels as reported in human skeletal muscle and liver
(Peeters et al., 2003; Weetman et al., 2003). While, using a knock-
out mice model for MCT8 (Mct8−/−) an increase in the plasma
free T4 and T3 levels, and D1 and D2 expression and activity in
the liver was shown (Dumitrescu et al., 2006). Therefore, these
results support the fact that low levels of T4 lead to changes in
the THT and deiodinase expression and activity in target organs.
However, there is no information addressing this possibility in
the human placenta from pregnancies coursing with maternal
hypothyroxemia.
On the other hand, minor changes such as D2 gene poly-
morphism (Thr92Ala) are associated with human type 2 dia-
betes mellitus and insulin resistance (Mentuccia et al., 2002).
In this regard, despite there is not information regarding D2
gene polymorphism in women coursing with pregnancies with-
out a diagnosis of thyroid gland pathology, a negative cor-
relation between free T4 level and metabolic markers of GD
and insulin resistance (i.e., degree of glycosylated HbA1c, fast-
ing insulin, and HOMA-IR) has been shown (Bassols et al.,
2011). Then, it is proposed that a potential relationship
between low maternal free T4 levels and occurrence of GD
and perhaps its complications including endothelial dysfunction
exists.
MATERNAL T4 LEVEL AND GD
GD is a disease coursing with glucose intolerance first recog-
nized or manifested during pregnancy [Metzger et al., 2007; Reece
et al., 2009; American Diabetes Association [ADA], 2012]. This
pathology accounts for ∼5% of pregnant women worldwide and
it is associated with high risk of fetal perinatal alterations (e.g.,
macrosomia, insulin resistance) and higher incidence of diseases
in the adulthood (e.g., GD, obesity, dyslipidemia, hypertension,
metabolic syndrome) (Poston, 2010; Negrato et al., 2012). GD
is associated with reduced maternal circulating T4 levels in the
first trimester of pregnancy. To date, 5% of women coursing
with GD pregnancies have been shown to correlate with IMH
(Krcma et al., 2010). In addition, free T4 levels are lower in women
with GD pregnancy compared with women with normal preg-
nancies (Velkoska-Nakova et al., 2010) and a reduced free T4 level
is shown in 70% of patients with GD pregnancies (Olivieri et al.,
2000). Therefore, maternal hypothyroxemia could be associated
with GD.
Other pathologies associated with low levels of free T4, such
as clinical hypothyroidism (i.e., low free T4 and high TSH lev-
els), also have been associated with GD. Indeed, 6–15% of
GD pregnancies are associated with hypothyroidism (Velkoska-
Nakova et al., 2010; Tudela et al., 2012; Stohl et al., 2013).
Moreover, if pregnant women have hypothyroidism, they have
4.3-fold higher risk for developing GD (Karakosta et al., 2012).
There are no publications addressing the T4 plasma levels at
the fetal circulation in a pregnancy coursing with GD. How-
ever, since GD courses with endothelial dysfunction (De Vriese
et al., 2000; Westermeier et al., 2011; Guzmán-Gutiérrez et al.,
2011, 2014; Salomón et al., 2012) and thyroid hormones modu-
late endothelial function (Napoli et al., 2001; Fazio et al., 2004),
it is likely that a low free T4 level at the maternal circulation
eventually could result in altered endothelial function in GD
pregnancies.
GD AND ENDOTHELIAL DYSFUNCTION
One of the main alterations detected in GD pregnancies is the
associated endothelial dysfunction of the fetoplacental circula-
tion (De Vriese et al., 2000; Guzmán-Gutiérrez et al., 2011, 2014;
Westermeier et al., 2011; Salomón et al., 2012). Since the vas-
culature in the human placenta lacks innervation (Marzioni
et al., 2004), several local metabolic mechanisms, such as syn-
thesis and release of vasoactive molecules (e.g., NO, adenosine)
(Vásquez et al., 2004; Guzmán-Gutiérrez et al., 2011, 2014; Sobre-
via et al., 2011) or release of nanovesicles (e.g., exosomes),
most likely mediating autocrine and/or paracrine modulation
of vasculature (Salomon et al., 2013), could lead to acute
and rapid modulation of vascular tone in this vascular bed
(Guzmán-Gutiérrez et al., 2011, 2014; Burnstock and Novak,
2013).
Arteries and veins in the humanplacenta frompregnancieswith
GD exhibit increased NO synthesis (Figueroa et al., 2000). Fur-
thermore, similar results were early reported in primary cultures
of HUVEC from pregnant women diagnosed with GD (Sobrevia
et al., 1995). Therefore, it has been proposed that vascular dysfunc-
tion inGDcould result froma functional dissociation betweenNO
synthesis and its bioavailability in the human placental circulation
(Guzmán-Gutiérrez et al., 2011, 2014; Sobrevia et al., 2011). Even
when endothelial dysfunction, referred to as an alteration of NO
synthesis and the uptake of cationic amino acid L-arginine (i.e., L-
arginine/NO pathway), is associated with GD, a clear mechanism
behind these effects of GD is still unavailable (Guzmán-Gutiérrez
et al., 2014).
HUMAN PLACENTA ENDOTHELIAL FUNCTION AND T4 IN GD:
A HYPOTHESIS TO BE TESTED
In normal pregnancies maternal free T4 is taken up by THT by
the syncytiotrophoblast, where it is metabolized by D2 and D3 to
be converted into T3 or rT3, respectively. T4 is then released via
THT at the basolateral membrane of the syncytiotrophoblast into
the intervillous space from where it is taken up by the microvas-
cular endothelial cells via THT. In these cells a fraction of T4
is metabolized again to produce T3 and rT3 via D2 and D3,
respectively (Figure 2). As a result of this process, T4 and T3
are released into the fetal blood. However, currently there is no
information regarding transport of thyroid hormones across the
human placenta in GD pregnancies. We propose that low lev-
els of T4, lead to an increase in the number and activity of
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FIGURE 2 | Potential thyroid hormones transplacental transport in
gestational diabetes. In cells from normal pregnancies (Normal ) T3 andT4 in
the maternal blood are transported to the fetal blood by thyroid hormone
transporters (THT) through the microvascular endothelium (Endothelium). T3
andT4 are metabolized by deiodinases 2 (D2, formingT3) and 3 (D3, forming
reverseT3 9 [T3 fromT4 and diiodothyronine (DIT) fromT3)], thus leading to
modulation of these hormones delivery to the fetal blood. As hypothesis, in
Gestational diabetes the mother courses with reducedT3 andT4 levels (red
arrows). There is an increaseTHT and reduced D2/D3 activity, thus
compensatingT4 level in the fetal blood.
THT membrane transporters available at the plasma membrane
of the human placental endothelial cells, and reduced deiodi-
nase expression and activity, in order to supply T4 necessities
associated with fetal development in GD. These changes could
constitute a mechanism by which the endothelium from the
human placenta intends to maintain normal intracellular and
circulating levels of T4 in the fetus. The latter would be poten-
tially reached by a greater delivery of maternal T4 to the fetal
blood.
FINAL COMMENTS AND CONCLUSION
Based on what was described in this review, our central research
questions are: (1) is a low level of free T4 in the maternal cir-
culation associated with GD? (2) is GD a disease associated with
increased placental THT, but reduced deiodinase expression and
activity? and (3) would the potential changes caused by reduced
free T4 level in the maternal circulation and altered THT and
deiodinases in the placenta in GD lead to placental endothe-
lial dysfunction? Furthermore, nothing is known regarding the
feto-placental vascular function/dysfunction in pregnancies where
the mother courses with hypothyroxemia. Despite many bene-
fits for using human placental tissue after birth, we acknowledge
that information behind cellular mechanisms and adaptative
response occurred at the beginning of pregnancy is difficult to
extrapolate; however, it offers a good approximation for study-
ing consequences of human pathologies. Potential more complex
models, might include analysis of placentas collected from ani-
mal deficient in leptin receptor (db/+), since they develop GD
during pregnancy (Bobadilla et al., 2010), offering a model that
may to understand molecular mechanisms of THT and deiodi-
nases in first trimester of pregnancy. Moreover, a therapeutical
approach of pregnant women coursing with hypothyroxemia tar-
geted to improve free T4 circulating levels will likely reduce
the risk of developing GD and the deleterious consequences
of this disease in the feto-placental endothelial function. We
also speculate that a normalization of free T4 levels in the first
trimester of pregnancy could reduce the risk to face GD-associated
complication.
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